Johnson & Johnson Innovation announced today the extension of the Johnson & Johnson Innovation Partnering Office at Monash University's Clayton Campus in Melbourne (JJIPO@Monash) in collaboration with the Victorian State Government.
This joint initiative between Johnson & Johnson Innovation, the Victorian Government and Monash University will be extended for approximately two years through June 30, 2023. The agreement will allow JJIPO@Monash to continue connecting with the Victorian innovation ecosystem, nurturing and accelerating innovative research, new product development and commercialisation for a global market, as well as boost local job creation in Victoria.
"Our collaboration with Monash University represents Johnson & Johnson Innovation's ongoing commitment to foster diverse healthcare ecosystems across Australia. This extension will further help connect life-science innovators in Victoria to accelerate their healthcare solutions across the globe," said Stacy Feld, Regional Head, Johnson & Johnson Innovation LLC, West North America, Australia & New Zealand.
Since 2012, Johnson & Johnson Innovation has played an active role in establishing connections with key stakeholders in the Australia life-science ecosystem, including academia, government and venture capitalists, to enable public-private collaboration and support early-stage entrepreneurs and academic researchers. JJIPO@Monash was originally launched in 2018 to provide crucial support to researchers and companies in the Victorian life-science sector as part of the Government's commitment to the medical technologies and pharmaceuticals sector – one of eight priority growth sectors. The public-private partnership between Johnson & Johnson Innovation, Monash University and the Victorian Government is one of only three such offices located across the world.
"Victoria has one of the world's largest life science clusters composed of medical technologies (medtech), biotechnologies and biological pharmaceutical industries. It's home to a vibrant commercial sector, key R&D infrastructure and advanced manufacturing expertise making it a highly sought-after destination by global healthcare companies," said Jaala Pulford, Minister for Innovation, Parliament of Victoria. "This is why we are delighted to extend our joint agreement with Johnson & Johnson Innovation to maintain the partnering office at Monash."
"This contract extension demonstrates the valuable work that is taking place at JJIPO@Monash," said Kathy Connell, Senior Director, Early Innovation Partnering, Australia & New Zealand, Janssen-Cilag Pty Ltd. "Several high impact Victorian healthcare collaborations have been signed since our launch, including those novel medical technologies and treatments for neurodegenerative and autoimmune conditions, and solutions for significant unmet needs in global public health including maternal mortality and infectious diseases."
Since its inception in 2018, JJIPO@Monash has provided a platform for major life-science collaboration in Victoria to strengthen the healthcare ecosystem and enable future impact, including:
St. Vincent's Institute of Medical Research (SVI)'s multi-year research collaboration with Janssen Pharmaceuticals, Inc. to develop and potentially commercialise small molecule modulators of microglial function and inflammation for Alzheimer's disease treatment
Monash University to support the development of an inhaled form of oxytocin as a life-saving therapy to prevent and manage postpartum haemorrhage (PPH) and Walter and Eliza Hall Institute of Medial Research (WEHI)'s collaborative research team to further develop potential antimalarial drugs from chemical compounds in the Janssen Jump-stARter Molecular Library (a collection of 80,000+ drug-like compounds designed to fast track the discovery of new medicines) – both collaborations with Janssen Pharmaceutical NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson
Monash University's multi-year research collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advanc...
Read More
(All Rights Reserved)